Yahoo Finance

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has ...
Yahoo Finance

AIRNA Presents Data Supporting RNA Editing Approach for Alpha-1 Antitrypsin Deficiency (AATD) at 28th ASGCT Annual Meeting

AIRNA is expected to file clinical trial application for optimized product candidate (AIR-001) with potential best-in-class profile for AATD in 2H 2025 CAMBRIDGE, Mass. &, TÜBINGEN, Germany, May 13, ...
Nasdaq

Editas Medicine to Present Key Preclinical Data on Gene Editing Advancements at ASGCT and TIDES Conferences

Editas Medicine presents preclinical data on gene editing at ASGCT, aiming to develop candidates for hematopoietic and liver therapies by 2025. Editas Medicine, Inc. announced its progress in the ...
FierceBiotech

JPM 2022: Editas, which caught flak in 2021 for limited gene editing data, will try to layer on the proof in 2022

Editas Medicine released a tiny drop of data last year as a proof of concept for its gene editing platform. Now, the CRISPR/Cas9 biotech will spend 2022 trying to back that up. We’re going to hear ...
Business Wire

Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human primates that ...